Form 4: Fulcrum Therapeutics Director Katina Dorton Reports Stock Option Grant

Director Katina Dorton reports the acquisition of stock options in Fulcrum Therapeutics, Inc.

Summary

• Katina Dorton, a director of Fulcrum Therapeutics, Inc., filed a Form 4 on June 18, 2024, reporting a transaction.
• The transaction involved the acquisition of 30,000 stock options with an exercise price of $7.
• These options were granted on June 17, 2024, and vest on the first anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• Following the reported transaction, Dorton beneficially owns 30,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates